In HER2-positive gastroesophageal adenocarcinoma, a disease where median overall survival rarely cleared 15 months with older regimens, zanidatamab plus tislelizumab and chemotherapy produced a median OS of 29.7 months in PD-L1-negative patients — nearly double the 15.8 months seen in the trastuzumab control arm. That number matters more than the headline trial result, because it dismantles the foundational assumption that PD-1 inhibitors require PD-L1 expression to deliver meaningful survival benefit in this tumor type.
The HERIZON-GEA-01 Phase 3 data, now published in the New England Journal of Medicine after their ASCO GI debut, show both zanidatamab-containing arms significantly outperformed trastuzumab plus chemotherapy on progression-free survival — median 12.4 versus 8.1 months, hazard ratios in the 0.63–0.65 range. The triple combination arm (zanidatamab plus tislelizumab plus chemotherapy) cleared statistical significance for OS at a hazard ratio of 0.72. The doublet arm’s OS data remain immature, with a second interim analysis expected mid-2026. Critically, the PFS and OS gains held across geographic region, ECOG performance status, and, most provocatively, PD-L1 status defined by both tumor area positivity score and combined positive score at 26 months of follow-up.
The mechanism behind PD-L1-agnostic benefit is not incidental. Zanidatamab’s bispecific design hits two non-overlapping HER2 epitopes and drives complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis — immune effector pathways that operate independently of PD-L1 expression. This creates a plausible mechanistic basis for why adding a PD-1 inhibitor to zanidatamab amplifies antitumor immunity even in tumors previously considered immunologically cold by checkpoint inhibitor standards. The subsequent-therapy analysis adds nuance: more patients in the trastuzumab arm received HER2-targeted and checkpoint therapies after progression, which means the OS benefit in the zanidatamab arms is not inflated by favorable post-progression treatment — it survives that confound intact.
Jazz has submitted the full dataset to NCCN for guideline inclusion, and additional PD-L1 subgroup analyses arrive at ASCO this week. The single number to track: the zanidatamab-plus-chemotherapy doublet’s OS at the mid-2026 interim analysis. If that arm clears a similar OS threshold without a PD-1 inhibitor, it reframes how much of the benefit is HER2-directed versus checkpoint-mediated — and determines whether oncologists have a chemotherapy-sparing or checkpoint-sparing path forward in this setting.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
